Drug Database
AT

atorvastatin strontium (Newvast)

✓ Approved

Hanmi Pharmaceutical · HMGCR · Small Molecule

What is atorvastatin strontium?

atorvastatin strontium is a small molecule developed by Hanmi Pharmaceutical. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesNewvast
CompanyHanmi Pharmaceutical
Drug ClassSmall Molecule
Molecular TargetHMGCR
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Hanmi Pharmaceutical

Mechanism of Action

Molecular Targets

atorvastatin strontium acts on 1 molecular target:

HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

atorvastatin strontium is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved
Metabolism and nutrition disordersHyperlipidaemia✓ Approved

Related Research Articles

PubMedMedicina clinica2026-08-24

Comparative efficacy and safety of rosuvastatin versus atorvastatin after acute ischemic stroke or transient ischemic attack: A systematic review and exploratory meta-analysis.

Cueva-Cañola Luis E LE, Beltran-De la Fuente Andrea C AC, Ramírez Navarro Diana I DI, Carrión-Cuéllar Astrid G AG et al.

Acute ischemic stroke (AIS) and transient ischemic attack (TIA) are leading causes of mortality and disability. High-intensity statins are central to secondary prevention, with guidelines recommending atorvastatin or rosuvastatin; however, comparative evidence post-stroke is limited. This study systematically reviewed literature comparing both agents after AIS/TIA. The protocol was registered in PROSPERO (CRD420261287374). PubMed, Embase, and Ovid MEDLINE were searched from inception to January 17, 2026, using predefined terms for statins and AIS/TIA. Five studies were included (one randomized trial and four cohort studies). Compared with atorvastatin, rosuvastatin was associated with greater improvements in lipid and inflammatory markers. Despite these differences, rates of recurrent stroke and all-cause mortality were similar between treatments. However, rosuvastatin was associated with lower rates of hemorrhagic stroke and more favorable composite cardiovascular outcomes. Evidence suggests biological differences but is insufficient to establish clinical superiority of either statin.

PMID 42636678
Read full article →
PubMedBMJ case reports2026-08-24

An uncommon side effect of statins: perioral neuropathic symptoms.

Anis Kerolus H KH, Malaty John J

A male patient in his 60s, with a history of hypertension and hyperlipidaemia, presented with a sensation of dryness, itchiness, numbness and tingling around his mouth that started after taking atorvastatin, suggesting a small-fibre neuropathy related to statin use. He was prescribed statins based on increased 10-year atherosclerotic cardiovascular disease risk (9.7%) and hyperlipidaemia. This observed side effect subsided when the medication was stopped. Evaluation was conducted to rule out other underlying aetiologies of his symptoms, and it was confirmed that the statins were the cause of the symptoms when two additional repeat statin trials, with both atorvastatin and rosuvastatin, caused similar side effects that promptly resolved within a few days of stopping the medications.

PMID 42637515
Read full article →
PubMedAtherosclerosis2026-08-24

Real-world variability and factors associated with individual low-density-lipoprotein cholesterol response to different doses of atorvastatin, rosuvastatin, and simvastatin in 28,647 Chinese patients.

Liao Yuexi Y, Cheung Wai Ki Keith WKK, Akyea Ralph K RK, Tomlinson Brian B et al.

Clinical guidelines recommend statin intensities based on average low-density lipoprotein cholesterol (LDL-C) lowering in clinical trials, but individual response in routine care, especially among non-White patients, is not well described. We therefore aimed to quantify individual LDL-C response and variability of statins in real-world practice in Hong Kong Chinese. This cohort study included 28,647 incident statin users (2004-2019) with or without cardiovascular diseases from Hong Kong's public healthcare system. Absolute and percentage changes in LDL-C at one year were assessed by statin type and daily dose (1-<10, 10-<20, 20-80 mg). Generalized estimating equations were used to identify predictors of individual LDL-C response in mmol/L. Despite a modest dose-response trend in absolute LDL-C reduction, interindividual variability was profound, from >80% reductions to >200% increases on the same statin and dose. Across all statin types and dose groups, over 30% of patients exhibited a suboptimal LDL-C response, while each group also included individuals achieving reductions of at least 50%. Greater LDL-C response was associated with more potent statin, higher statin dose, men, older age, chronic kidney disease, diabetes, and higher baseline LDL-C. This study demonstrates a discordance between the fixed statin intensities recommended in clinical guidelines and the high interindividual variability observed in clinical practice. While low-dose statin initiation is effective at the population level in Hong Kong, variability in LDL-C response supports personalized statin dosing and follow-up monitoring of LDL-C.

PMID 42636576
Read full article →
PubMedActa biomaterialia2026-08-23

Silicate Biomaterials Modulate Heart-Bone Paracrine Interactions for Tissue Repair.

Jin Kenan K, Wang Zhixu Z, Du Lin L, Zhang Hongjian H et al.

The repair of tissue injuries involving complex inter-tissue interactions remains challenging because conventional biomaterials are usually designed to target individual tissues. This study focuses on heart-bone paracrine interactions and proposes a biomaterial-based strategy to modulate reciprocal communication between cardiac- and bone-related cells for tissue repair. We show that strontium silicate (SS) biomaterials release bioactive Sr2+ and Si species that promote the functional activation of encapsulated CMs and bone marrow stromal cells, while also reshaping their secretory profiles. Using 3D-bioprinted co-culture models and local implantation in rodent injury models, we demonstrate that SS-modulated BMSC-laden constructs promote cardiac repair after myocardial infarction, whereas SS-modulated CM-laden constructs enhance cranial bone regeneration. Mechanistically, these effects are associated with altered secretion of candidate paracrine factors, including IGF-1, SDF-1, and BMP-2, and functional involvement of PI3K/AKT and MAPK/ERK signaling pathways. These findings suggest that silicate biomaterials may act as upstream regulators of heart-bone paracrine interactions by combining transient ionic stimulation with secondary remodeling of cellular secretory profiles. This study provides a proof-of-concept strategy for biomaterial-regulated inter-tissue communication and tissue repair. STATEMENT OF SIGNIFICANCE: This study introduces the concept of using silicate biomaterials to facilitate beneficial communication between the heart and bone for coordinated repair. We demonstrate that strontium silicate releases bioactive ions and modulates key signaling factors (SDF-1, IGF-1, BMP-2), activating PI3K/AKT and MAPK/ERK pathways. This not only enhances cardiac function recovery but also promotes bone healing in rat disease models. To our knowledge, this is the first report demonstrating a single biomaterial orchestrating multi-organ interactive repair by targeting inter-organ crosstalk.

PMID 42633815
Read full article →
PubMedJACC. Case reports2026-08-22

Severe Multivessel Coronary Artery Disease in an Adolescent With Genetic Dyslipidemia.

Thorsen Venessa V, Slim George G, Saskikumar Navaneetha N, Bainey Kevin R KR et al.

Familial hypercholesterolemia is characterized by lifelong elevations in low-density lipoprotein cholesterol (LDL-C) that, when left untreated, markedly increase the risk of premature atherosclerotic cardiovascular disease (ASCVD). Although ASCVD is common in adults with familial hypercholesterolemia, events in adolescence are rare. A 14-year-old man presented with exertional chest pain and mild troponin elevation. Myocarditis was initially suspected, but the persistence of symptoms prompted advanced imaging, revealing multivessel ASCVD. LDL-C was severely elevated (9 mmol/L, 350 mg/dL). Atorvastatin and ezetimibe lowered LDL-C to ≤1.4 mmol/L (<55 mg/dL). Multivessel percutaneous coronary intervention resulted in resolution of symptoms and inducible ischemia. A heterozygous APOE p.(Leu167del) pathogenic variant was identified, an uncommon cause of heterozygous familial hypercholesterolemia (HeFH). Similarly severe dyslipidemia was identified in the 6-year-old brother. This particularly aggressive and genetically unique form of HeFH resulted in premature ASCVD from adolescence. Early detection and treatment prevent catastrophic cardiovascular events in HeFH; cascade screening is essential for at-risk relatives.

PMID 42631674
Read full article →
PubMedFood research international (Ottawa, Ont.)2026-08-22

Oral co-delivery of quercetin and anthocyanins via dual-ligand nanoparticles alleviate obesity and associated metabolic disorders.

Zhang Hui H, Liu Chunmei C, Yang Jiahao J, Li Shanglin S et al.

Obesity is a global epidemic driven in part by poor oral bioavailability of bioactive food compounds. Here, we develop dual-ligand-functionalized nanoparticles (NPs) for the oral co-delivery of hydrophilic anthocyanins (ACN) and hydrophobic quercetin (Que) to combat obesity. The system is assembled from lactobionic acid-modified chitosan (LACS) and glycyrrhetinic acid-modified casein (GACA), forming a core-shell structure that protects both compounds against gastrointestinal degradation and affords pH-responsive colloidal stability. In Caco-2/HT29-MTX-E12 co-culture models, the LACS-ACN-GACA-Que NPs enhance intestinal absorption via energy-dependent endocytosis, facilitate transcellular transport, and achieve sustained intracellular accumulation. Orally administered to high-fat diet-induced obese mice, the NPs surpass both the unencapsulated bioactive mixture and the clinical drug atorvastatin in reducing body weight gain, white adipose tissue hypertrophy, hepatic steatosis, and systemic inflammation. These anti-obesity benefits are accompanied by favorable gut microbiota remodeling: enrichment of short-chain fatty acid-producing taxa (Oscillospiraceae, Ruminococcaceae, Lachnospiraceae) and suppression of pro-inflammatory lineages (Erysipelotrichaceae). Collectively, this dual-ligand strategy establishes a versatile oral delivery platform that protects and synergistically delivers disparate bioactive compounds, offering a promising approach for obesity management.

PMID 42632694
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about atorvastatin strontium